281 Emerging Technologies in Pharmaceutical Research and Manufacturing


Description:
This session seeks presentations that research on new and innovative technologies in an effort to improve the development of active pharmaceutical ingredients. Abstracts relating to novel process designs to achieve product specifications, separations, methods for novel chemical synthesis, and scale up of chemistry and unit operations are of interest. Advancements in experimental, theoretical, and computational tools will be discussed pertaining to these researches. Case studies relating to small and medium molecules are welcomed.

Sponsor:
Pharmaceutical Discovery, Development and Manufacturing Forum
Co-Sponsor(s):
Pharmaceuticals (15B)


Chair:
Shujauddin M. Changi
Sr Consultant Engineer
Eli Lilly and Company
2300 Hayward Street
Indianapolis, IN
48109
Email: smchangi@lilly.com

Co-Chair:
David A. Acevedo
U.S. Food and Drug Administration
Silver Spring, MD
47906
Phone Number: 7872469515
Email: David.Acevedo@fda.hhs.gov


Papers:
281a
Convergent Synthesis of Peptides at Large Scale
Nil Tandogan, Eli Lilly and Company; Kevin Seibert, Eli Lilly and Company; Neil Kallman, Eli Lilly and Company; Jennifer M. Groh, Eli Lilly and Company; Shankarraman Vaidyaraman, Eli Lilly and Company; Michael Kopach, Eli Lilly and Company
281b
Continuous N-Hydroxyphthalimide Mediated Electrochemical Aerobic Oxidation of Benzylic C-H Bonds
Yiming Mo, Massachusetts Institute of Technology; Klavs F. Jensen, Massachusetts Institute of Technology
281c
Future Manufacturing Platforms
Carla Luciani, Eli Lilly and Company; Kevin Seibert, Eli Lilly and Company; Colm O'Mahony, Eli Lilly; Adam D. McFarland, Eli Lilly and Company; Krizia Karry, Eli Lilly; Wyatt Roth, SMDD; Michael Frederick, Eli Lilly; Martin Johnson, Eli Lilly and Company; Sarah O'Keeffe, Eli Lilly; Paul Collins, Eli Lilly
281d
Harnessing Power of Membranes to Enable Simultaneous Crystallization of Two Isomers
Manish S. Kelkar, Abbvie Inc.; Daniel Weyant, Abbvie Inc.; Rajarathnam E Reddy, Abbvie Inc.; John Bellettini, Abbvie Inc.; Nandkishor K. Nere, AbbVie Inc.
281e
Nanofiltration: Integration in Small and Medium Molecule Processes
Shujauddin M. Changi, Eli Lilly and Company; Nicholas Klitzing, Eli Lilly and Company; Kevin Seibert, Eli Lilly and Company; Nil Tandogan, Eli Lilly and Company; Neil Kallman, Eli Lilly and Company; Michael Kopach, Eli Lilly and Company; Carla Luciani, Eli Lilly and Company; Christopher Lippelt, Eli Lilly and Company; Justin Burt, Eli Lilly and Company; Michael Laurila, Eli Lilly and Company; Joeseph Martinelli, Eli Lilly and Company
281f
Liquid Phase Oligonucleotide Synthesis with Membrane Separation for Efficient Large Scale Manufacturing
Danilo Cuccato, Imperial College London; Jack H. J. Cordrey, Imperial College London; Piers Gaffney, Imperial College London; Patrizia Marchetti, Imperial College London; Jeong F. Kim, Imperial College London; Daniela Negru, GSK, Medicines Research Centre; Mike Anson, GSK, Medicines Research Centre; Andrew G. Livingston, Imperial College London
Abstract Submissions Closed
See more of this Group/Topical: Pharmaceutical Discovery, Development and Manufacturing Forum
<< Previous Session | Next Session >>